-
GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang
•
China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the expansion of its manufacturing facility for oligonucleotide and peptide products at Zhenjiang, Jiangsu province. This strategic move aims to enhance the company’s production capabilities to meet the growing demand for these specialized products. Enhanced Oligonucleotide…
-
Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a Phase I/II clinical study for its first-in-class bispecific antibody (BsAb), BPB-101. The molecule is currently being assessed for the treatment of advanced malignant solid tumors. BPB-101: A Trifunctional IgG1 Subtype Humanized AntibodyBPB-101 is a trifunctional…
-
Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
•
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its first-in-class CD24 monoclonal antibody (mAb), ATG-031. The Phase I PERFORM study is designed to assess the safety, tolerability, pharmacological properties, immunogenicity,…
-
BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment
•
BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the National Medical Products Administration (NMPA) to treat CD20 positive diffuse large B-cell lymphoma, non-specific (DLBCL, NOS) in adults. The approval is for the use of zuberitamab in combination with standard cyclophosphamide, doxorubicin, vincristine, and prednisone…
-
WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants
•
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for two COVID-19 protein vaccines co-developed in collaboration with West China Hospital, Sichuan University. These vaccines are specifically targeting the XBB variant and other emerging strains, including the recombinant bivalent COVID-19 protein…
-
CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer
•
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of patient enrollment for a Phase II clinical study of its CT041 in advanced gastric cancer/esophageal gastric junction adenocarcinoma (GC/GEJ) with positive CLDN18.2 expression that has previously failed at least second-line treatment. CT041:…
-
National Vaccine & Serum Institute Partners with Corning Life Sciences to Foster Innovation
•
The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming to cultivate innovation talents and promote the exploration of novel technologies in new fields. The collaboration focuses on advancing scientific research and technological development without disclosing any financial details. Corning Life Sciences: A Leader in…
